EVT.DE
XETRAEvotec SE
Healthcare · Drug Manufacturers - Specialty & Generic
Why is it down?
no visible trigger- ·From its high of €3.85 on 12/08/2026 the price fell 27.7% to €2.81.
- ·The biggest single-day drop was 7.8% on 13/08/2026.
- ·No clear news driver in the last 10 days.
- ·The market as a whole is calm, so this drop is specific to the company.
- ·Other Drug Manufacturers - Specialty & Generic stocks we track are down only 6.1% on average, so this is mostly about the company. See all 13 in this sector →
A drop without a visible trigger is often selling pressure, not new facts. That is the kind of dip the engine looks for, but it is still a guess, not a promise.
Verdict
signal 2 h agoA dip is in progress: 27.7% below its 30-day high, but the fall has not shown a bottom yet. Wait; the verdict turns to Buy when at least 3 of 5 bottom checks pass.
Catalysts
3 h ago- News, last 10 days
- no recent news
- Next earnings
- 05/11/2026 · in 49 days
- Last report
- 05/11/2025 -81.1% vs estimate
Trade levels
Why the engine says so
History for this ticker
Watch and alert
About Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. It has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. The company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
- Headquarters:
- Hamburg, Germany
- 52-week range:
- €2.77 – €7.30
- Website:
- evotec.com
Signals are generated automatically from price, volume and technical indicators. They are not investment advice.← Back to search